Ortin Laboratories Ltd.
Snapshot View

26.00 0.00

18 May 2022, 04:01:00 PM
Volume: 1,618

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.ortinlabsindia.com
Market Cap 20.90 Cr.
Enterprise Value(EV) 28.06 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 1.06 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 24.36 Trailing Twelve Months Ending 2021-12
Industry PE 28.96 Trailing Twelve Months Ending 2021-12
Book Value / Share 14.04 Trailing Twelve Months Ending 2021-12
Price to Book Value 1.83 Calculated using Price: 25.70
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 0.81 Cr. 8,131,392 Shares
FaceValue 10
Company Profile

Ortin Laboratories established in the year 1986  was a private limited company with a nominal capital of Rs 1 lakh to offer quality drugs and medicines to the suffering mankind. Later, in the year 1994, this private limited company converted as a public limited company with 5,060 shareholders which received good subscription from the public. These proceeds were utilised for constructing a factory in a spacious area of 25000 sq feet with all ultra-modern infrastructure as per the WHO GMP Standards to manufacture the complete range of Pharmaceutical Formulations of Tablets, Capsules, Syrups, Dry Powders & Ointments. Due to its concern for quality, the company stands as a leading and predominant pharmaceutical manufacturer of drugs and medicines of the country with turnover running in crores of rupees.

Quality is the hallmark of Ortin. At every stage of production from raw material to finished products, highest standard of quality is ensured with the help of most modern equipment and experienced personnel.This unflinching perseverance towards quality has helped the company to earn enormous goodwill & trust, both from medical profession and pharmaceutical trade.

Being in partnership with the world means respecting its resources without compromise and so at Ortin, continuous process evaluation and monitoring waste recoveries ensure that the focus is maintained. Specialized facilities have helped us to earn a reputation for the expert handling of hazardous materials in the form of reactants and products. Teams from the ministry of health regularly inspect the company's plant. Every care is taken for treatment of solid wasters, discharged liquids and atmospheric releases.

Ortin is contemplating an entry into the OTC segment as part of its long term growth strategy. It is channeling its efforts towards building an overseas marketing network in order to enhance exports to third world countries. Ortin proposes to be certified as a WHO GMP Unit and to launch innovative Biotechnology products in Orthopedic and Dental Segments. The success behind them is only the Reliance which they carry for their Quality from the people all over the country. Their motto, right from their inception has been towards Quality and they still maintain them and continue to do so in future.

Products manufactured by the company include:

  • Capsules
  • Syrups / Dry syrups
  • Powders
  • Second Division Products
  • Generic Products

Achievements/ recognition :

  • Ortin has been certified as an ISO 9001: 2000 company by the internationally recognized Quality Management Certification Body, the National Quality Assurance, UK in pursuance of its focus towards Quality with its Policy to enhance customer satisfaction by providing Quality Pharmaceutical Formulations at optimum cost and maintain profitability through continual improvement of Quality Management Sytems and cGMP.
  • Ortin is honored as a registered Supplier of Drugs & Medicines with the most reputed Central, State & Quasi-Government Organizations & Institutions of our Country such as the Railways, Health Ministry, Defence, Posts & Telegraph, Electricity Hospitals, Transport Organizations, Research Institutions such as JIPMER, IICT etc.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
+11.59%
1 Month
-6.31%
3 Month
-6.64%
6 Month
-8.29%
1 Year
-13.33%
2 Year
+127.07%
5 Year
+36.84%
10 Year
-6.47%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 5.34 5.55 4.04 3.65 2.16 2.86 5.21 -2.31 5.38
Return on Capital Employed (%) 15.05 13.62 11.55 11.01 9.58 10.14 11.76 8.93 3.27
Return on Assets (%) 1.40 1.62 1.28 1.25 0.79 1.00 1.43 -0.51 1.37

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 21 22 22 23 23 24 25 24 11 12
Non Curr. Liab. 4 6 8 16 8 8 8 9 2 2
Curr. Liab. 49 45 37 27 31 42 72 84 8 8
Minority Int.
Equity & Liab. 73 73 68 66 62 74 105 117 21 22
Non Curr. Assets 27 26 24 35 23 21 23 24 15 15
Curr. Assets 46 47 44 31 38 52 82 92 6 7
Misc. Exp. not W/O 0
Total Assets 73 73 68 66 62 74 105 117 21 22

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 75 67 60 63 67 80 168 197 8 8
Other Income 0 1 0 1 0 0 1 0 0 0
Total Income 75 68 61 64 67 80 168 198 8 8
Total Expenditure -68 -61 -54 -57 -61 -74 -162 -192 -7 -7
PBIDT 7 7 7 6 6 6 7 6 1 1
Interest -4 -4 -4 -3 -3 -3 -3 -3 -1 -1
Depreciation -1 -2 -2 -2 -2 -2 -2 -2 0 0
Taxation -1 -1 0 -1 -1 -1 -1 1 1
Exceptional Items
PAT 1 1 1 1 1 1 1 -1 1 1
Adjusted EPS 1 1 1 0 0 0 1 0 1 1

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 0 -2 -2 -1 1 2 2 7 3 18
Cash Fr. Inv. -2 -2 0 0 -1 -1 -1 -3 -3 0
Cash Fr. Finan. 2 5 1 2 0 -1 0 -3 -1 -10
Net Change 0 1 -1 1 0 0 1 0 -1 8
Cash & Cash Eqvt 1 2 1 2 2 -14 -13 -13 -14 -5

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 34.84 34.84 34.84 34.84 10.40 15.68 15.68 15.68 15.68
Public 65.16 65.16 65.16 65.16 89.60 84.32 84.32 84.32 84.32
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 16 May 2022
Board Meeting Intimation for Consideration Of Audited Financial Results For The Quarter And Year Ended 31.03.2022
Ortin Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve audited financial results for the quarter and year ended 31.03.2022
Thu, 14 Apr 2022
Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Nitesh Kumar Sharma
Designation :- Company Secretary and Compliance Officer
Wed, 13 Apr 2022
Compliances Certificate Under Reg. 7(3)
Compliances certificate under reg. 7(3)

Technical Scans View Details

Wed, 18 May 2022
High Decrease 1 Month High Decrease 1 Month
High Increase 2 Years High Increase 2 Years
Closing Near 50 SMA Closing Near 50 SMA
Close Crossing 50 SMA From Above Close Crossing 50 SMA From Above
Closing Near 20 SMA Closing Near 20 SMA

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 215,700.21 899.00 +0.8%
Divi's Laboratories Ltd. 115,623.51 4,355.45 +1.2%
Cipla Ltd. 76,889.38 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. 65,126.60 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. 53,689.19 3,734.00 -2.1%
Gland Pharma Ltd. 51,396.43 3,122.95 +0.6%
Piramal Enterprises Ltd. 47,255.41 1,980.00 -0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.47 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-12 45.03 4,355.45 +1.2%
Cipla Ltd. Consolidated 2022-03 30.55 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-12 24.64 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 47.37 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-12 43.33 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-12 38.03 1,980.00 -0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.17 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-12 10.67 4,355.45 +1.2%
Cipla Ltd. Consolidated 2022-03 3.69 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-12 3.39 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.70 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-12 7.48 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-12 1.33 1,980.00 -0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 0.10 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,980.00 -0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 14.13 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,980.00 -0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 14.13 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,980.00 -0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,980.00 -0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,980.00 -0.2%